View all Press Releases

Acerus Announces Addition of Chief Medical Officer

07/21/2020

Dr. Chris Sorli, MD, PhD, FACE Joins Acerus’ Executive Leadership

TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB: ASPCF) today announced that Dr. Christopher Sorli, MD, PhD, FACE will join the Company as Chief Medical Officer, effective August 3, 2020, and will become a member of Acerus’ Senior Leadership Team.

“I am very pleased to announce that Dr. Sorli is joining the Company in this important new role as we lay the foundation for growth in the quarters to come,” said Ed Gudaitis, President and CEO of Acerus. “Chris has an outstanding background in medical affairs, product development, and clinical practice, which we believe will be critical to our future success. We look forward to his scientific and analytical leadership across our medical activities and business development initiatives.”

Prior to joining Acerus, Dr. Sorli was the Vice President US Medical Affairs & Head of Cardio-Metabolic Disease for Sanofi (NASDAQ: SNY). In this role, he was responsible for all US medical affairs activities for diabetes, cardiovascular issues, metabolic diseases, and integrated care solutions for a diverse portfolio of products at various stages across the product lifecycle. From 2016 – 2018 he was the Global Medical Lead for New Products with the Diabetes and Cardiovascular Business Unit at Sanofi, where he provided medical input into early clinical development candidates. Prior to his time at Sanofi, Dr. Sorli founded and led the Billings Clinic Diabetes, Endocrinology and Metabolism Center, a large state-wide centre of excellence in endocrinology in Montana. While in clinical practice, one of his clinical specialties was men's health.

Dr. Sorli completed his medical training at the University of Massachusetts Medical School, his internship and residency at Beth Israel Hospital in Boston, and his fellowship at the University of Minnesota. He is Board Certified in Endocrinology, Diabetes and Metabolism, and Internal Medicine. He is nationally and internationally recognized as a Key Opinion Leader for Diabetes, Obesity and Metabolism. Dr. Sorli has been the principal investigator on numerous industry-sponsored clinical studies, a member of several advisory boards, an invited lecturer, and an FDA AdCom presenter.

About Acerus

Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health. The Company commercializes its products via its own salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.

Acerus’ shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.

Notice Regarding Forward-Looking Statements

Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, and could differ materially from what is currently expected as set out above. In particular, these assumptions include but are not limited to, the following: the COVID-19 pandemic will not affect our business plan and that of our suppliers, the COVID-19 pandemic will not last many months and health care professionals will be available to hear about our products and to continue education programs related to them. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 3, 2020 which is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

Company Contact
ir@aceruspharma.com

Investor Relations Contact
Chris Witty
Acerus Investor Relations
(646) 438-9385
cwitty@darrowir.com

Source: Acerus Pharmaceuticals Corporation